Scholars@Duke
Mustafa Khasraw

Mustafa Khasraw

Professor of Neurosurgery
Neurosurgery

Selected Publications

Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.

Journal Article J Neurooncol · November 21, 2024 Glioblastoma (GBM), the most common and aggressive primary central nervous system (CNS) tumor in adults, continues to have a dismal prognosis. Across hundreds of clinical trials, few novel approaches have translated to clinical practice while survival has ... Full text Link to item Cite

Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.

Journal Article Neuro Oncol · October 24, 2024 Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in patients with malignant gliomas have shown some early promise in pediatric and adult patients. However, the long-term benefits and safety for patients remain to be established. Th ... Full text Link to item Cite

A brave new framework for glioma drug development.

Journal Article Lancet Oncol · October 2024 Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Ini ... Full text Link to item Cite

The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.

Journal Article Cancer Immunol Res · June 4, 2024 Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate the whole-genome and long-read transcript sequencing of cancers to identify the collection of neo-open reading frame peptides (NOP) expressed in tumo ... Full text Link to item Cite

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.

Journal Article Adv Ther · May 2024 INTRODUCTION: Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis. During the disease course, 25-50% of patients will develop BrMs. Despite availabl ... Full text Link to item Cite

Immune Checkpoint Inhibitors in Geriatric Oncology.

Journal Article Curr Oncol Rep · May 2024 PURPOSE OF REVIEW: This manuscript will update prior reviews of immune checkpoint inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of cancer immunology and aging. RECENT FINDINGS: ICIs have led to significan ... Full text Link to item Cite

Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.

Journal Article Neurooncol Pract · April 2024 BACKGROUND: Isocitrate dehydrogenase (IDH) is commonly mutated (mIDH) in gliomas, and this mutant enzyme produces the oncometabolite 2-hydroxyglutarate (2HG). 2HG promotes gliomagenesis and is implicated in epileptogenesis. Ivosidenib (IVO), a small molecu ... Full text Link to item Cite

Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02)

Conference Breast · April 1, 2024 Introduction, A decade ago, stereotactic radiosurgery (SRS) without whole brain radiotherapy (WBRT) was emerging as preferred treatment for oligometastatic brain metastases. Studies of cavity SRS after neurosurgery were underway. Data specific to metastati ... Full text Cite

Soluble immune-checkpoint factors: a potential immunotherapy biomarker.

Journal Article J Clin Invest · April 1, 2024 There is unmet need for additional biomarkers to better select patients with non-small cell lung cancer (NSCLC) that are likely to benefit from immunotherapy in order to improve patient outcomes, reduce patient toxicity, and relieve the growing burden of h ... Full text Link to item Cite

The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.

Journal Article Cancer Res · March 4, 2024 UNLABELLED: Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and r ... Full text Link to item Cite

Comparing Knowledge and Perceptions of Palliative Care Among Neuro-Oncology Patients, Caregivers, and Providers to a Representative U.S. Sample

Conference American Journal of Hospice and Palliative Medicine · January 1, 2024 Background: Primary brain tumors (PBTs) pose a significant health challenge, affecting patients and their caregivers. While early integration of palliative care (PC) has shown benefits in advanced cancer, its integration for PBT patients, particularly glio ... Full text Cite

Dendritic cell vaccine trials in gliomas: Untangling the lines.

Journal Article Neuro Oncol · October 3, 2023 Glioblastoma is a deadly brain tumor without any significantly successful treatments to date. Tumor antigen-targeted immunotherapy platforms including peptide and dendritic cell (DC) vaccines, have extended survival in hematologic malignancies. The relativ ... Full text Link to item Cite

Characterization of industry relationships in oncology.

Conference Cancer · September 15, 2023 BACKGROUND: Collaborative relationships between academic oncology and industry (pharmaceutical, biotechnology, "omic," and medical device companies) are essential for therapeutic development in oncology; however, limited research on engagement in and perce ... Full text Link to item Cite

CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.

Journal Article Nat Cancer · September 2023 The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex (MHC) class I (MHC-I) molecules. Likewise, ... Full text Link to item Cite

[18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial.

Journal Article BMJ Open · August 4, 2023 INTRODUCTION: Glioblastoma is the most common aggressive primary central nervous system cancer in adults characterised by uniformly poor survival. Despite maximal safe resection and postoperative radiotherapy with concurrent and adjuvant temozolomide-based ... Full text Link to item Cite

National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities.

Journal Article Lancet Oncol · August 2023 Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient surviv ... Full text Link to item Cite

Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma.

Journal Article BioDrugs · July 2023 Glioblastoma is highly aggressive and remains difficult to treat despite being the most common malignant primary brain tumor in adults. Current standard-of-care treatment calls for maximum resection of the tumor mass followed by concurrent chemotherapy and ... Full text Link to item Cite

Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.

Journal Article Curr Neurol Neurosci Rep · June 2023 PURPOSE OF REVIEW: The management of isocitrate dehydrogenase (IDH)-wildtype glioblastomas is an area of unmet need. Despite multimodal therapy incorporating maximal safe resection, radiotherapy, and temozolomide, clinical outcomes remain poor. At disease ... Full text Link to item Cite

Interdependencies of the Neuronal, Immune and Tumor Microenvironment in Gliomas.

Journal Article Cancers (Basel) · May 21, 2023 Gliomas are the most common primary brain malignancy and are universally fatal. Despite significant breakthrough in understanding tumor biology, treatment breakthroughs have been limited. There is a growing appreciation that major limitations on effective ... Full text Link to item Cite

Hope in the era of precision oncology: a qualitative study of informal caregivers' experiences.

Journal Article BMJ Open · May 2, 2023 OBJECTIVES: To explore informal caregivers' perspectives on precision medicine in cancer care. DESIGN: Semi-structured interviews with the informal caregivers of people living with cancer and receiving targeted/immunotherapies. Interview transcripts were a ... Full text Link to item Cite

The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice.

Journal Article Clin Cancer Res · May 1, 2023 For three years, COVID-19 has circulated among our communities and around the world, fundamentally changing social interactions, health care systems, and service delivery. For people living with (and receiving treatment for) cancer, pandemic conditions pre ... Full text Link to item Cite

Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Conference Cancer Research · April 14, 2023 AbstractBackground: GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Phase 2/3 Response Adaptive Randomization platform tria ... Full text Cite

Abstract 4924: Alternative lengthening of telomeres is associated with hypersensitivity to topoisomerase 1 inhibition in glioblastoma xenograft models

Conference Cancer Research · April 4, 2023 AbstractGlioblastoma (GBM), the most common primary malignant brain tumor in adults, is an incurable disease that has an inevitable tendency to recur following standard of care surgery, radiotherapy, and tem ... Full text Cite

Abstract 3193: Developing non-exhausted tumor infiltrating lymphocytes (TILs) as a therapy for glioblastoma

Conference Cancer Research · April 4, 2023 AbstractGlioblastoma is the most prevalent primary brain malignancy, with a median survival of less than 21 months despite treatment with surgery, radiation, and chemotherapy. Significant intra-tumoral heter ... Full text Cite

Abstract 4061: Systemic autologous lymphocyte transfer can enhance tumor-infiltrating lymphocyte infiltration in glioblastoma and license co-stimulatory immunotherapy

Conference Cancer Research · April 4, 2023 AbstractGlioblastoma is an immunologically ‘cold’ malignancy where few tumor infiltrating lymphocytes (TILs) are present. We sought to overcome this by ‘seeding’ the tumor with TILs via administration of aut ... Full text Cite

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.

Journal Article Lancet Oncol · April 2023 Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series ... Full text Link to item Cite

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.

Journal Article NPJ Breast Cancer · March 30, 2023 Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinic ... Full text Link to item Cite

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.

Journal Article Neuro Oncol · January 5, 2023 BACKGROUND: Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit. The a ... Full text Link to item Cite

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.

Journal Article Neurooncol Adv · 2023 BACKGROUND: Serclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We investigated Ser-T m ... Full text Link to item Cite

NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.

Journal Article Neurooncol Adv · 2023 BACKGROUND: There is an immunologic rationale to evaluate immunotherapy in the older glioblastoma population, who have been underrepresented in prior trials. The NUTMEG study evaluated the combination of nivolumab and temozolomide in patients with glioblas ... Full text Link to item Cite

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.

Journal Article Asia Pac J Clin Oncol · December 2022 AIM: Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This study evaluated outcomes and safety in patients treated with palboci ... Full text Link to item Cite

Patterns of care in adult histone mutant gliomas: Results of an international survey.

Journal Article Neurooncol Pract · December 2022 BACKGROUND: Histone mutant gliomas (HMG) with histone H3 K27 and G34 mutations are recognized as biologically discrete entities with distinct anatomical locations, younger age at presentation (in comparison to the most common high-grade gliomas, IDH wildty ... Full text Link to item Cite

Living (well) with cancer in the precision era

Journal Article SSM - Qualitative Research in Health · December 1, 2022 Surviving cancer in the precision era of targeted drugs and immunotherapies increasingly involves surviving-with malignancy. Against this backdrop of precision, innovation and chronicity, this paper offers a person-centred examination of some of the emergi ... Full text Cite

NCOG-43. A RETROSPECTIVE ANALYSIS OF THE IMPACT OF THE COVID-19 INFECTION ON NEURO-ONCOLOGY CARE AND PATIENT OUTCOMES: A TWO-SITE STUDY

Conference NEURO-ONCOLOGY · November 14, 2022 BACKGROUND COVID-19 radically changed neuro-oncology care. In this retrospective study, we examine the impact of COVID-19 infection on neuro-oncological care and clinical outcomes in two geographically separate populations. METHODS Descriptive statistics ... Full text Link to item Cite

EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms.

Journal Article Int J Mol Sci · November 7, 2022 Neuroendocrine neoplasms (NENs) are relatively rare neoplasms occurring predominantly in the gastrointestinal tract and pancreas. Their heterogeneity poses challenges for diagnosis and treatment. There is a paucity of markers for characterisation of NEN tu ... Full text Link to item Cite

Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma.

Journal Article Nat Commun · October 29, 2022 Glioblastoma (GBM) is notorious for its immunosuppressive tumor microenvironment (TME) and is refractory to immune checkpoint blockade (ICB). Here, we identify calmodulin-dependent kinase kinase 2 (CaMKK2) as a driver of ICB resistance. CaMKK2 is highly ex ... Full text Link to item Cite

P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma

Conference Neuro-Oncology · September 5, 2022 AbstractBackgroundGBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, internat ... Full text Cite

Glioma progression is shaped by genetic evolution and microenvironment interactions.

Journal Article Cell · June 9, 2022 The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA sequencing data from the temporally separated tumor pairs of 304 adult patients wit ... Full text Link to item Cite

Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective.

Journal Article Asia Pac J Clin Oncol · June 2022 AIM: The neuro-oncology community in Australia is well positioned to collaborate internationally, with a motivated trials group, strong regulatory bodies and an attractive fiscal environment. We sought to identify gaps in the Australian neuro-oncology clin ... Full text Link to item Cite

Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.

Journal Article Clin Cancer Res · May 13, 2022 PURPOSE: To investigate the antitumor activity of a mitochondrial-localized HSP90 inhibitor, Gamitrinib, in multiple glioma models, and to elucidate the antitumor mechanisms of Gamitrinib in gliomas. EXPERIMENTAL DESIGN: A broad panel of primary and temozo ... Full text Link to item Cite

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.

Journal Article Cancers (Basel) · February 16, 2022 Gliomas are the most common malignant primary brain tumor in adults. Despite advances in multimodality therapy, incorporating surgery, radiotherapy, systemic therapy, tumor treating fields and supportive care, patient outcomes remain poor, especially in gl ... Full text Link to item Cite

Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.

Journal Article Clin Cancer Res · February 15, 2022 Immunotherapy has revolutionized treatment for many hard-to-treat cancers but has yet to produce significant improvement in outcomes for patients with glioblastoma. This reflects the multiple and unique mechanisms of immune evasion and escape in this highl ... Full text Link to item Cite

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.

Journal Article Clin Cancer Res · February 15, 2022 Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for N ... Full text Link to item Cite

Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis.

Journal Article World neurosurgery · February 2022 IntroductionAs many as 30% of patients with non-small cell lung cancer (NSCLC) will develop brain metastases (BMs) over the course of their illness. Here, we quantitatively compare the efficacy of the various emerging regimens for NSCLC BMs withou ... Full text Cite

Experiencing the SARS-CoV-2 Pandemic Whilst Living With Cancer.

Journal Article Qual Health Res · February 2022 The SARS-CoV-2 pandemic has resulted in considerable consequences for many cancer patients, exacerbating pre-existing systemic health system limitations as well as creating new challenges. From socially distanced clinics and the widespread introduction of ... Full text Link to item Cite

New Approaches to Glioblastoma.

Journal Article Annu Rev Med · January 27, 2022 Faced with unique immunobiology and marked heterogeneity, treatment strategies for glioblastoma require therapeutic approaches that diverge from conventional oncological strategies. The selection and prioritization of targeted and immunotherapeutic strateg ... Full text Link to item Cite

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.

Journal Article Clin Cancer Res · January 1, 2022 Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action-based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial ... Full text Link to item Cite

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma.

Journal Article Neurooncol Adv · 2022 BACKGROUND: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data w ... Full text Link to item Cite

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When injected dir ... Full text Link to item Cite

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: High-grade gliomas (HGGs) are immunologically ‘cold’ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ... Full text Link to item Cite

NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA

Conference NEURO-ONCOLOGY · 2022 Abstract BACKGROUND Nivolumab is a PD-1 inhibitor with known safety profile. An increase in mutations as we age is well documented in glioblastoma and other cancers. Higher mutational load is associated with increased response to nivolumab in extracranial ... Full text Link to item Cite

LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.

Journal Article BMJ Open · December 30, 2021 INTRODUCTION: Grades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3 gliomas at progression approach the dismal outcomes for glioblastoma (GBM), yet there is a paucity ... Full text Link to item Cite

A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.

Journal Article Clin Cancer Res · December 15, 2021 PURPOSE: To investigate the therapeutic role of a novel telomere-directed inhibitor, 6-thio-2'-deoxyguanosine (THIO) in gliomas both in vitro and in vivo. EXPERIMENTAL DESIGN: A panel of human and mouse glioma cell lines was used to test therapeutic effica ... Full text Link to item Cite

QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThere is increasing recognition that palliative care (PC) can benefit patients with advanced cancers. However, ear ... Full text Open Access Link to item Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference Neuro-Oncology · November 12, 2021 AbstractIsocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for t ... Full text Open Access Link to item Cite

INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThe use of telemedicine increased during the COVID-19 pandemic. However, the impact on patient satisfaction in the ... Full text Open Access Cite

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma.

Journal Article J Immunother Cancer · November 2021 Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have ... Full text Link to item Cite

The microenvironment of brain metastases from solid tumors.

Journal Article Neurooncol Adv · November 2021 Brain metastasis (BrM) is an area of unmet medical need that poses unique therapeutic challenges and heralds a dismal prognosis. The intracranial tumor microenvironment (TME) presents several challenges, including the therapy-resistant blood-brain barrier, ... Full text Link to item Cite

A sociology of precision-in-practice: The affective and temporal complexities of everyday clinical care.

Journal Article Sociol Health Illn · November 2021 The idea of 'precision medicine', which has gained increasing traction since the early 2000s, is now ubiquitous in health and medicine. Though varied in its implementation across fields, precision medicine has raised hopes of revolutionary treatments and h ... Full text Link to item Cite

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.

Conference Neuro Oncol · October 1, 2021 BACKGROUND: Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant po ... Full text Link to item Cite

Leveraging external data in the design and analysis of clinical trials in neuro-oncology.

Journal Article Lancet Oncol · October 2021 Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision making (eg, early stop ... Full text Link to item Cite

Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.

Journal Article Cells · August 9, 2021 Despite the important evolution of immunotherapeutic agents, brain tumors remain, in general, refractory to immune therapeutics. Recent discoveries have revealed that the glioma microenvironment includes a wide variety of immune cells in various states tha ... Full text Link to item Cite

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.

Journal Article Neuro Oncol · August 2, 2021 On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various stakeholders from the brain tumor community participated including ... Full text Link to item Cite

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.

Journal Article J Immunother Cancer · July 2021 With rapid advances in our understanding of cancer, there is an expanding number of potential novel combination therapies, including novel-novel combinations. Identifying which combinations are appropriate and in which subpopulations are among the most dif ... Full text Link to item Cite

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · June 1, 2021 AbstractIntroductionThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Link to item Cite

Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.

Conference Journal of Clinical Oncology · May 20, 2021 1091 Background: Tumor mutational burden (TMB) has emerged as an imperfect biomarker of immune checkpoint inhibition (ICI) outcomes in solid tumors. Despite the approval for pembrolizumab in all TMB-high (TMB-H) solid tumors, the ... Full text Cite

GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2021 TPS2074 Background: GBM AGILE, Glioblastoma Adaptive, Global, Innovative Learning Environment, is an international, multi-arm, seamless phase 2/3 response adaptive randomization platform trial designed to evaluate multiple therap ... Full text Cite

A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.

Conference Journal of Clinical Oncology · May 20, 2021 2585 Background: CDX-527 is a bispecific antibody (BsAb) targeting PD-L1 and CD27 that is designed to block immune checkpoint PD-L1/PD-1 interactions while providing immune costimulation through CD27 signaling. CD27 is a key immu ... Full text Cite

The role of immunotherapy in fusion-driven lung cancer.

Journal Article Expert Rev Anticancer Ther · May 2021 Full text Link to item Cite

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

Journal Article Ann Oncol · May 2021 BACKGROUND: High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer app ... Full text Link to item Cite

mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.

Journal Article BMC Gastroenterol · April 27, 2021 BACKGROUND: Neuroendocrine neoplasms (NENs) are a complex group of tumours that occur in many organs. Routinely used IHC markers for NEN diagnosis include CgA, synaptophysin, Ki67 and CD56. These have limitations including lack of correlation to clinical o ... Full text Link to item Cite

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.

Journal Article Cochrane Database Syst Rev · April 22, 2021 BACKGROUND: Locally advanced and metastatic breast cancer remains a challenge to treat. With emerging study results, it is important to interpret the available clinical data and apply the evidence offering the most effective treatment to the right patient. ... Full text Link to item Cite

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

Journal Article Clin Cancer Res · March 1, 2021 Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the majority of patients have primary or acquired resistance to these immunotherapies. ... Full text Link to item Cite

Salting the Soil: Targeting the Microenvironment of Brain Metastases.

Journal Article Mol Cancer Ther · March 2021 Paget's "seed and soil" hypothesis of metastatic spread has acted as a foundation of the field for over a century, with continued evolution as mechanisms of the process have been elucidated. The central nervous system (CNS) presents a unique soil through t ... Full text Link to item Cite

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.

Journal Article J Immunother Cancer · February 2021 BACKGROUND: CD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated wit ... Full text Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal Article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram.

Journal Article Neurooncol Adv · 2021 BACKGROUND: Glioblastoma (GBM) is the most common primary malignant brain tumor in adulthood. Despite multimodality treatments, including maximal safe resection followed by irradiation and chemotherapy, the median overall survival times range from 14 to 16 ... Full text Link to item Cite

Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.

Journal Article Neurooncol Adv · 2021 BACKGROUND: For patients with recurrent glioblastoma (rGBM), there are few options following treatment failure with radiotherapy plus temozolomide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the ... Full text Link to item Cite

Targeting Immunometabolism in Glioblastoma.

Journal Article Front Oncol · 2021 We have only recently begun to understand how cancer metabolism affects antitumor responses and immunotherapy outcomes. Certain immunometabolic targets have been actively pursued in other tumor types, however, glioblastoma research has been slow to exploit ... Full text Link to item Cite

Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis.

Journal Article Frontiers in oncology · January 2021 BackgroundBrain metastases (BM) from non-small-cell lung cancer (NSCLC) are frequent and carry significant morbidity, and current management options include varying local and systemic therapies. Here, we performed a systematic review and network m ... Full text Cite

Highlights from the Literature

Journal Article Neuro-Oncology · January 1, 2021 Full text Cite

Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases.

Journal Article Front Oncol · 2021 Brain metastases cause significant morbidity and mortality in patients with advanced cancer. In the era of precision oncology and immunotherapy, there are rapidly evolving systemic treatment options. These novel therapies may have variable intracranial eff ... Full text Link to item Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference NEURO-ONCOLOGY · 2021 Isocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for the gliomagenesis associated with these tumors and the pro ... Full text Link to item Cite

What is the Burden of Proof for Tumor Mutational Burden in gliomas?

Journal Article Neuro Oncol · November 30, 2020 The treatment of patients with a variety of solid tumors has benefitted from immune checkpoint inhibition targeting the anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis. The US Food and Drug Administration (FDA) granted accel ... Full text Link to item Cite

The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts.

Journal Article Clin Cancer Res · November 15, 2020 Coronavirus disease 2019 (COVID-19) has fundamentally disrupted the practice of oncology, shifting care onto virtual platforms, rearranging the logistics and economics of running a successful clinical practice and research, and in some contexts, redefining ... Full text Link to item Cite

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · November 9, 2020 AbstractINTRODUCTIONThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Open Access Link to item Cite

PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Journal Article Clin Cancer Res · October 15, 2020 Glioblastoma (WHO grade IV glioma) is the most common malignant primary brain tumor in adults. Survival has remained largely static for decades, despite significant efforts to develop new effective therapies. Immunotherapy and especially immune checkpoint ... Full text Link to item Cite

Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic.

Journal Article Clin Cancer Res · July 1, 2020 The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has necessitated changes in cancer care delivery as resources are reallocated. Clinical trials and other research activities are inevitably impacted. Start-up activities for new tria ... Full text Link to item Cite

Management of glioblastoma: State of the art and future directions.

Journal Article CA Cancer J Clin · July 2020 Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. The standard approa ... Full text Link to item Cite

WITHDRAWN: The epidemiology of emergency presentations for falls across Western Victoria, Australia.

Journal Article Australas Emerg Care · June 27, 2020 The Publisher regrets that this article is an accidental duplication of an article that has already been published, https://doi.org/10.1016/j.auec.2019.08.003. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdraw ... Full text Link to item Cite

The epidemiology of emergency presentations for falls from height across Western Victoria, Australia.

Journal Article Australas Emerg Care · June 2020 BACKGROUND: In order to implement intervention strategies to prevent falls from height, epidemiological data are needed. The aim of this study was to map emergency presentations for falls from height in residents aged ≥40yr of the western region of Victori ... Full text Link to item Cite

Anti-epidermal growth factor receptor therapy for glioblastoma in adults.

Journal Article Cochrane Database Syst Rev · May 12, 2020 BACKGROUND: Glioblastoma is an uncommon but highly aggressive type of brain tumour. Significant gains have been achieved in the molecular understanding and the pathogenesis of glioblastomas, however clinical improvements are difficult to obtain for many re ... Full text Link to item Cite

The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.

Journal Article Clin Transl Radiat Oncol · May 2020 BACKGROUND AND PURPOSE: Current practice in re-irradiation (reRT) of previously treated high-grade gliomas (HGG) has generally been limited to small volume reRT with stereotactic procedures. Less evidence exists for large volume reRT involving treatment vo ... Full text Link to item Cite

Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.

Journal Article Int J Mol Sci · February 19, 2020 The management of non-small cell lung cancer (NSCLC) has transformed with the discovery of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene fusions or rearrangements form a unique sub-class, with anaplastic lymp ... Full text Link to item Cite

Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts

Conference Cancer Research · February 15, 2020 AbstractBackground: Avelumab, a human IgG1 anti–PD-L1 monoclonal antibody, has shown antitumor activity and a manageable safety profile in several tumor types. Talazoparib, an orally available PARP inhibitor ... Full text Cite

Molecular and clonal evolution in recurrent metastatic gliosarcoma.

Journal Article Cold Spring Harb Mol Case Stud · February 2020 We discuss the molecular evolution of gliosarcoma, a mesenchymal type of glioblastoma (GBM), using the case of a 37-yr-old woman who developed two recurrences and an extracranial metastasis. She was initially diagnosed with isocitrate dehydrogenase (IDH) w ... Full text Link to item Cite

Driving innovation through collaboration: Development of clinical annotation datasets for brain cancer biobanking

Journal Article Neuro-Oncology Practice · January 31, 2020 Background: A key component of cancer research is the availability of clinical samples with appropriately annotated clinical data. Biobanks facilitate research by collecting/storing various types of clinical samples for research. Brain Cancer Biobanking Au ... Full text Cite

Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.

Journal Article Strahlenther Onkol · January 2020 PURPOSE: The current study aimed to assess patterns of failure (PoF) in anaplastic glioma (AG) patients managed with intensity-modulated radiation therapy (IMRT) and their relationship to molecular subtype. METHODS: The outcomes of AG patients managed betw ... Full text Link to item Cite

Highlights from the Literature

Journal Article Neuro-Oncology · January 1, 2020 Full text Cite

Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention.

Journal Article JMIR Res Protoc · December 3, 2019 BACKGROUND: Online information resources and support have been demonstrated to positively influence the well-being of people diagnosed with cancer. This has been explored in past literature for more common cancers; however, for rare cancers, such as neuroe ... Full text Link to item Cite

MYCN amplification drives an aggressive form of spinal ependymoma.

Journal Article Acta Neuropathol · December 2019 Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous system ... Full text Link to item Cite

The epidemiology of emergency presentations for falls across Western Victoria, Australia.

Journal Article Australas Emerg Care · December 2019 BACKGROUND: In order to develop and implement prevention strategies for falls, comprehensive epidemiological data are required. Therefore, this study mapped emergency presentations for falls across the western region of Victoria, Australia, encompassing ur ... Full text Link to item Cite

Longitudinal molecular trajectories of diffuse glioma in adults.

Journal Article Nature · December 2019 The evolutionary processes that drive universal therapeutic resistance in adult patients with diffuse glioma remain unclear1,2. Here we analysed temporally separated DNA-sequencing data and matched clinical annotation from 222 adult patients with glioma. B ... Full text Link to item Cite

Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.

Journal Article Cancer · October 1, 2019 BACKGROUND: Patients with anaplastic glioma (AG) harboring an isocitrate dehydrogenase mutation have potential durable survival after intensity-modulated radiotherapy (IMRT) and chemotherapy. Understanding long-term functioning, and the factors that have a ... Full text Link to item Cite

Mapping Cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women.

Journal Article BMC Cancer · September 6, 2019 BACKGROUND: Cancer is a leading burden of disease in Australia and worldwide, with incidence rates varying with age, sex and geographic location. As part of the Ageing, Chronic Disease and Injury study, we aimed to map the incidence rates of primary cancer ... Full text Link to item Cite

Traveling With Cancer: A Guide for Oncologists in the Modern World.

Journal Article J Glob Oncol · July 2019 PURPOSE: Travel for patients with cancer has become more achievable because of gains in quality of life and overall survival. The risk assessment of these patients is complex, and there is a paucity of data to which clinicians can refer. We present the cha ... Full text Link to item Cite

Revision joint replacement surgeries of the hip and knee across geographic region and socioeconomic status in the western region of Victoria: a cross-sectional multilevel analysis of registry data.

Journal Article BMC Musculoskelet Disord · June 25, 2019 BACKGROUND: Residents of rural and regional areas, compared to those in urban regions, are more likely to experience geographical difficulties in accessing healthcare, particularly specialist services. We investigated associations between region of residen ... Full text Link to item Cite

Association between area-level socioeconomic status, accessibility and diabetes-related hospitalisations: a cross-sectional analysis of data from Western Victoria, Australia.

Journal Article BMJ Open · May 22, 2019 OBJECTIVE: Hospitalisation rates for many chronic conditions are higher in socioeconomically disadvantaged and less accessible areas. We aimed to map diabetes hospitalisation rates by local government area (LGA) across Western Victoria, Australia, and inve ... Full text Link to item Cite

A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).

Conference Journal of Clinical Oncology · May 20, 2019 2011 Background: TMZ offers minimal benefit in uMGMT GBM pts. V is synergistic with both RT and TMZ in preclinical models, safe when combined with either RT or TMZ clinically, but the triplet (V+RT+TMZ) is poorly tolerated. This ... Full text Cite

Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

Conference Journal of Clinical Oncology · May 20, 2019 2042 Background: The VERTU trial (ANZCTR #ACTRN12615000407594) compared Arm A (standard of care) = RT (60Gy/30 fractions) + TMZ (75mg/m2 daily) followed by TMZ (150–200mg/m2 D1–5) every 2 ... Full text Cite

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.

Journal Article J Clin Oncol · May 1, 2019 PURPOSE: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing ... Full text Link to item Cite

Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.

Journal Article J Med Imaging Radiat Oncol · April 2019 INTRODUCTION: Assess survival of patients with anaplastic glioma (AG) and the relationship to molecular subtype. METHODS: Patients with AG managed with IMRT between 2008 and 2014 were entered into a prospective database assessing relapse-free survival (RFS ... Full text Link to item Cite

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Journal Article Neuro Oncol · March 18, 2019 BACKGROUND: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines on the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsi ... Full text Link to item Cite

Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).

Journal Article Sci Rep · February 27, 2019 Recurrence in patients with glioblastoma (GBM) is inevitable resulting in short survival times, even in patients with O-6-Methylguanine-DNA Methyltransferase (MGMT) methylation. Other pathways must be activated to escape from temozolomide (TMZ) treatment, ... Full text Link to item Cite

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

Journal Article PLoS One · 2019 BACKGROUND: This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determina ... Full text Link to item Cite

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults

Journal Article The Cochrane database of systematic reviews · January 2019 Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the efficacy and harms of anti‐ therapies for glioblastoma. ... Cite

Profiles of brain metastases: Prioritization of therapeutic targets.

Journal Article Int J Cancer · December 1, 2018 We sought to compare the tumor profiles of brain metastases from common cancers with those of primary tumors and extracranial metastases in order to identify potential targets and prioritize rational treatment strategies. Tumor samples were collected from ... Full text Link to item Cite

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

Journal Article Clin Colorectal Cancer · December 2018 BACKGROUND: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 2 ... Full text Link to item Cite

Anti-angiogenic therapy for high-grade glioma.

Journal Article Cochrane Database Syst Rev · November 22, 2018 BACKGROUND: This is an updated version of the original Cochrane Review published in September 2014. The most common primary brain tumours in adults are gliomas. Gliomas span a spectrum from low to high grade and are graded pathologically on a scale of one ... Full text Link to item Cite

RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS

Journal Article Neuro-oncology · November 2018 Abstract BACKGROUND An increase of mutations as we age is well documented in GBM and in cancer in general. Elderly patients with GBM may have higher mutational burden and may be more likely to respond to immunotherapies. NUTMEG is a randomised Pha ... Cite

EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS

Journal Article Neuro-oncology · November 2018 Abstract BACKGROUND We have previously published a Cochrane meta-analysis of the efficacy of anti-angiogenic therapy (AAT) in high grade glioma (HGG) in 2014. Since this time, a number of key trials have been published. An updated meta-analysis wa ... Cite

ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM)

Journal Article Neuro-oncology · November 2018 Abstract BACKGROUND TGF- signaling promotes tumor immunosuppression; TGF- inhibition in the tumor microenvironment may enhance the response to antiPD-L1 treatment. M7824 is an innovative, first-in-class, bifunctional fusion protein composed of a h ... Cite

Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre.

Journal Article Brain Sci · October 15, 2018 Delivery of highly sophisticated, and subspecialised, management protocols for glioblastoma in low volume rural and regional areas creates potential issues for equivalent quality of care. This study aims to demonstrate the impact on clinical quality indica ... Full text Link to item Cite

Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma.

Journal Article Clin Oncol (R Coll Radiol) · September 2018 The recognition of specific molecular prognostic factors has altered the management of primary brain tumours over the past decade. These factors have allowed stratification of morphologically similar tumours into different prognostic groups and are now als ... Full text Link to item Cite

P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress

Journal Article Neuro-oncology · September 2018 Abstract Background TMZ with short course radiotherapy (RT) is an option for elderly GBM patients. Nivolumab is a PD-1 inhibitor with known safety profile in GBM. An increase of mutations as we age is well documented in GBM and in cancer in genera ... Cite

Correction to: Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.

Journal Article Arch Osteoporos · July 9, 2018 The names of the co-authors Steven Graves and Michelle Lorimer were missing from the manuscript supplied for publication. The lead authors regret this error and apologize for any inconvenience. ... Full text Link to item Cite

Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.

Journal Article Neuro Oncol · June 18, 2018 Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas and similar projects have provided a comprehensive understanding of the somatic alterations and molecula ... Full text Link to item Cite

Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.

Journal Article Intern Med J · June 2018 BACKGROUND: Magnetic resonance imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor receptor type-2 (HER2) subtype and Ki-67 proliferation index. Whether ... Full text Link to item Cite

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.

Journal Article Asia Pac J Clin Oncol · June 2018 AIM: Despite the considerable impact of neuroendocrine tumors (NETs) on patients' lives, the patient journey is not well documented. The aim of this survey was to identify the impact and burden of NETs from the patient perspective. METHODS: This was a self ... Full text Link to item Cite

Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Journal Article J Neurooncol · April 2018 Studies looking at the benefit of surgery at first relapse (second surgery) for recurrent glioblastoma were confounded by including patients with varying grades of glioma, performance status and extent of resection. This case-controlled study aims to remov ... Full text Link to item Cite

The epidemiology of hip fractures across western Victoria, Australia.

Journal Article Bone · March 2018 BACKGROUND: Hip fractures are associated with considerable morbidity and mortality. Hip fracture incidence varies across different levels of accessibility/remoteness and socioeconomic status (SES). As part of the Ageing, Chronic Disease and Injury Study, w ... Full text Link to item Cite

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Journal Article Clin Cancer Res · February 15, 2018 Glioblastoma (GBM) is a deadly disease with few effective therapies. Although much has been learned about the molecular characteristics of the disease, this knowledge has not been translated into clinical improvements for patients. At the same time, many n ... Full text Link to item Cite

AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.

Conference Journal of Clinical Oncology · February 1, 2018 TPS548 Background: Neuroendocrine carcinomas (NEC WHO grade 3) are rare and aggressive cancers. There are no randomised trials to date to establish standard therapy for advanced gastrointestinal (GI) NECs. Extrapolating from smal ... Full text Cite

The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection.

Journal Article Oncotarget · January 30, 2018 Glioblastoma presents as a heterogeneous disease with poor prognosis despite the use of multimodal therapy. Analysis of genomic DNA changes between initial diagnosis and recurrence in response to standard treatment protocols would enhance understanding of ... Full text Link to item Cite

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Journal Article Neuroendocrinology · 2018 BACKGROUND: In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients with pancreatic neuroendocrine tumours (panNETs). This study was a post-marketing commitment to support the phase III da ... Full text Link to item Cite

Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.

Journal Article Pract Radiat Oncol · 2018 AIM: The authors sought to evaluate the impact of 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) on radiation therapy planning for patients diagnosed with glioblastoma (GBM) and the presence of suspected nonenhancing tumors compared with ... Full text Link to item Cite

Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.

Journal Article Arch Osteoporos · November 6, 2017 UNLABELLED: Compared to urban residents, those in rural/regional areas often experience inequitable healthcare from specialist service providers. Independent of small between-area differences in utilisation, socially advantaged groups had the greatest upta ... Full text Link to item Cite

Evaluating the Causes of Screen Failures in a Medical Oncology Clinical Trial Unit

Conference ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY · August 1, 2017 Link to item Cite

Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.

Journal Article Int J Radiat Oncol Biol Phys · July 15, 2017 PURPOSE: To assess the outcomes of the most elderly cohort of patients with a diagnosis of glioblastoma multiforme (GBM) after intensity modulated radiation therapy (IMRT). METHODS AND MATERIALS: The data of patients with GBM who had underwent IMRT from Ma ... Full text Link to item Cite

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Journal Article N Engl J Med · July 13, 2017 BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epider ... Full text Link to item Cite

Immune Checkpoint Inhibitors for Brain Metastases.

Journal Article Curr Oncol Rep · June 2017 PURPOSE OF REVIEW: Metastasis of cancer to the brain typically portends a poor prognosis and often results in significant morbidity, including from the side effects of treatment. More effective therapies for patients with brain metastases are needed. The c ... Full text Link to item Cite

Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.

Conference Journal of Clinical Oncology · May 20, 2017 2062 Background: Recurrence in patients with glioblastoma (GBM) is inevitable, even in patients with O-6-Methylguanine-DNA Methyl Transferase ( MGMT) methylation. We identified increased expression of the inflammatory cytokine, M ... Full text Cite

Immune Checkpoint Inhibitors in Gliomas.

Journal Article Curr Oncol Rep · April 2017 PURPOSE OF REVIEW: Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hol ... Full text Link to item Cite

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.

Journal Article J Transl Med · March 17, 2017 BACKGROUND: The O 6 -methylguanine methyltransferase (MGMT) gene is frequently unmethylated in patients with glioblastoma (GBM), rendering them non-responsive to the standard treatment regime of surgery followed by concurrent radiotherapy (RT) and temozolo ... Full text Link to item Cite

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Journal Article Clin Transl Oncol · March 2017 Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatm ... Full text Link to item Cite

Management of breast cancer brain metastases: A practical review.

Journal Article Breast · February 2017 Brain metastases are a common, and frequently challenging, clinical problem in the contemporary management of metastatic breast cancer. While the management of extracranial metastatic breast cancer is now strongly defined by tumour phenotype, this approach ... Full text Link to item Cite

The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.

Conference Journal of Clinical Oncology · February 1, 2017 380 Background: Sunitinib was approved by the FDA in 2011 for treatment of progressive, well-differentiated, advanced pancreatic neuroendocrine tumors (pNETs) based on a pivotal phase III study (NCT00428597) that showed a signifi ... Full text Cite

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.

Journal Article Theranostics · 2017 Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the sup ... Full text Link to item Cite

Combination of palbociclib and radiotherapy for glioblastoma.

Journal Article Cell Death Discov · 2017 The cyclin-dependent kinase inhibitor, palbociclib has shown compelling efficacy in breast cancer patients. Several pre-clinical studies of glioblastoma (GBM) have also shown palbociclib to be efficacious. In this study, we investigated palbociclib in comb ... Full text Link to item Cite

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Journal Article Lung Cancer · December 2016 OBJECTIVES: The role of anti-angiogenic tyrosine kinase inhibitors (AATKI) for patients with non-small-cell lung cancers (NSCLC) is uncertain. We conducted a comprehensive meta-analysis to assess the overall utility of adding AATKI to chemotherapy. MATERIA ... Full text Link to item Cite

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Journal Article Neuro Oncol · October 2016 BACKGROUND: Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly ... Full text Link to item Cite

Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia).

Journal Article J Public Health Res · August 19, 2016 Background: An increasing burden of chronic disease and associated health service delivery is expected due to the ageing Australian population. Injuries also affect health and wellbeing and have a long-term impact on health service utilisation. There is a ... Full text Link to item Cite

Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre.

Journal Article Support Care Cancer · July 2016 PURPOSE: Data on the use of targeted therapies at the end of life are scarce. This study reviews the pattern of use of targeted and potentially futile, toxic, or costly therapies at an Australian cancer centre. METHODS: This retrospective single-centre rev ... Full text Link to item Cite

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Journal Article J Clin Oncol · July 1, 2016 PURPOSE: RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tumors ... Full text Link to item Cite

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Journal Article Oncoimmunology · June 2016 BACKGROUND: Emerging immunotherapeutic strategies for the treatment of glioblastoma (GBM) such as dendritic cell (DC) vaccines, heat shock proteins, peptide vaccines, and adoptive T-cell therapeutics, to name a few, have transitioned from the bench to clin ... Full text Link to item Cite

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Journal Article BMC Cancer · May 31, 2016 BACKGROUND: Patients with metastatic colorectal cancer whose disease has progressed on oxaliplatin- and irinotecan-containing regimens may benefit from EGFR-inhibiting monoclonal antibodies if they do not contain mutations in the KRAS gene (are "wild type" ... Full text Link to item Cite

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Journal Article J Neurooncol · May 2016 Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12 months. This phase II study investigated the efficacy and safety of combining the selective integrin inhibitor cilengitide with a com ... Full text Link to item Cite

Retrospective analysis of cancer survival across South-Western Victoria in Australia.

Journal Article Aust J Rural Health · April 2016 OBJECTIVE: This paper aims to describe cancer survival and examine association between survival and socio-demographic characteristics across Barwon South-Western region (BSWR) in Victoria, Australia. DESIGN: This study is based on the retrospective cohort ... Full text Link to item Cite

A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments.

Journal Article J Natl Compr Canc Netw · March 2016 BACKGROUND: This study sought to understand the preferences of patients with cancer and the trade-offs between appointment attributes using discrete choice experiment (DCE). METHODS AND STUDY DESIGN: Patients with cancer at 3 hospitals completed a self-adm ... Full text Link to item Cite

Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.

Journal Article Expert Rev Anticancer Ther · 2016 Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors derived from peptide- and amine-secreting cells of the neuroendocrine system. NETs commonly arise in the gastrointestinal tract but can arise in most organs of the body. Although the inc ... Full text Link to item Cite

Evolving management of low grade glioma: No consensus amongst treating clinicians.

Journal Article J Clin Neurosci · January 2016 Following the widely publicized presentation of the Radiation Therapy Oncology Group (RTOG) 9802 data, we sought to understand how these data had been translated to the management of low grade gliomas (LGG) by Australian neuro-oncology clinicians. The de n ... Full text Link to item Cite

Abstract A12: Genomically unstable glioblastoma are sensitive to Parp inhibition

Conference Cancer Research · December 1, 2015 AbstractBackground: The development of effective targeted drugs for the treatment of glioblastoma (GBM) represents a major unmet need. Veliparib (ABT-888; Abbvie) inhibits both PARP1 and PARP2 (poly[ADP-ribo ... Full text Cite

SYMPTOM BURDEN OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET)

Conference Asia-Pacific Journal of Clinical Oncology · November 1, 2015 Link to item Cite

CDK4/6 inhibitors in breast cancer.

Journal Article Anticancer Drugs · September 2015 Deregulation of the cyclin-dependent kinase (CDK) 4/6-retinoblastoma (RB) axis can occur through a number of mechanisms and contributes towards the unrestrained growth witnessed in a variety of cancers including breast cancers. Recent years have seen the d ... Full text Link to item Cite

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Journal Article N Engl J Med · July 16, 2015 BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibi ... Full text Link to item Cite

Mutational analysis of matched initial and recurrent TP53 WT primary GBM.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.

Journal Article Theranostics · 2015 Understanding the molecular basis of drug resistance and utilising this information to overcome chemoresistance remains a key challenge in oncology. Here we report that survivin, a key protein implicated in drug resistance, is overexpressed in cancer stem ... Full text Link to item Cite

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer

Journal Article Cochrane Database of Systematic Reviews · November 26, 2014 This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of PARP inhibitors for women with locally advanced or metastatic breast cancer. ... Full text Cite

Use of targeted therapy in cancer patients in the end-of-life period.

Journal Article Journal of Clinical Oncology · November 1, 2014 129 Background: There is limited data on the use of these targeted therapies in patients at the end of life. This study reviews the pattern of use of targeted and potentially futile, toxic and costly therapies at the end of life ... Full text Cite

Patterns of care in adult medulloblastoma: results of an international online survey.

Journal Article J Neurooncol · October 2014 The literature on medulloblastoma in adults is generally limited to case reports and retrospective series, and there is no accepted standard of care. The Cooperative Trials Group for Neuro-Oncology (COGNO) sought to determine the range and consistency of c ... Full text Link to item Cite

Abstract 3777: Combining VELIPARIB (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines

Conference Cancer Research · October 1, 2014 AbstractIntroduction: The survival trends for glioblastoma (GBM) patients have remained largely static, reflecting lack of improvement in the therapeutic options for patients. Less than 5% of newly diagnosed ... Full text Cite

Antiangiogenic therapy for high-grade glioma.

Journal Article Cochrane Database Syst Rev · September 22, 2014 BACKGROUND: The most common primary brain tumours in adults are gliomas. Gliomas span a spectrum from low to high-grade and are graded pathologically on a scale of one to four according to the World Health Organization (WHO) classification. High-grade glio ... Full text Link to item Cite

Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.

Journal Article Asia Pac J Clin Oncol · September 2014 AIM: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) are well established in treating metastatic pulmonary adenocarcinoma, especially patients with activating EGFR mutations. EGFR mutations are rare in pulmonary squa ... Full text Link to item Cite

A meta-analysis of antiangiogenic therapy for glioblastoma (GBM).

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.

Journal Article Expert Opin Biol Ther · May 2014 INTRODUCTION: Gliomas are highly vascular and rich in VEGF, which promotes angiogenesis. Bevacizumab is a monoclonal antibody against VEGF, inhibiting angiogenesis by preventing receptor activation. Early Phase II clinical trials using bevacizumab in both ... Full text Link to item Cite

Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry.

Journal Article BMJ Open · March 17, 2014 OBJECTIVES: Using the prediction of cancer outcome as a model, we have tested the hypothesis that through analysing routinely collected digital data contained in an electronic administrative record (EAR), using machine-learning techniques, we could enhance ... Full text Link to item Cite

Brain metastases in breast cancer.

Journal Article Expert Rev Anticancer Ther · February 2014 Despite therapeutic advances, the development of breast cancer brain metastases (BCBM) is still the harbinger of a dismal prognosis. Patient outcomes vary depending on factors, including tumor phenotype, extent of disease within and outside the brain, as w ... Full text Link to item Cite

A RETROSPECTIVE STUDY OF WOMEN WITH LATE PRESENTATIONS OF BREAST CANCER

Conference ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY · January 1, 2014 Link to item Cite

Emerging pharmacotherapy for cancer patients with cognitive dysfunction.

Journal Article BMC Neurol · October 24, 2013 Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The cytotoxic nature of chemothera ... Full text Link to item Cite

Patterns of care study of adult medulloblastoma.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2013 Link to item Cite

Small bowel video capsule endoscopy: an overview.

Journal Article Expert Rev Gastroenterol Hepatol · May 2013 Video capsule endoscopy (VCE) is being increasingly used to investigate small bowel pathology. It is the gold standard for obscure gastrointestinal bleeding and iron deficiency anemia. VCE has been in use since 2001 and indications for its use are expandin ... Full text Link to item Cite

Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.

Journal Article Cancer · April 1, 2013 BACKGROUND: This study sought to estimate the risk of breast cancer (BC) after a diagnosis of ovarian cancer (OC) associated with mutation of the BRCA1/2 (breast cancer, early onset) genes (BRCA-OC). METHODS: The Memorial Sloan-Kettering Cancer Center and ... Full text Link to item Cite

Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.

Journal Article Expert Rev Anticancer Ther · April 2013 Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of neoplasms derived from peptide- and amine-secreting cells of the neuroendocrine system. NENs commonly arise in the GI tract but can arise in most organs of the body. NENs in different organs ... Full text Link to item Cite

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Journal Article Neuro Oncol · February 2013 BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs). METHODS: Eligible patients received daily temozolomide (50 mg/m2) continuously until progression. ... Full text Link to item Cite

Intra-aortic metastases or intra-arterial thrombus?

Journal Article International Journal of Case Reports and Images · 2013 Full text Cite

Using lithium as a neuroprotective agent in patients with cancer.

Journal Article BMC Med · November 2, 2012 Neurocognitive impairment is being increasingly recognized as an important issue in patients with cancer who develop cognitive difficulties either as part of direct or indirect involvement of the nervous system or as a consequence of either chemotherapy-re ... Full text Link to item Cite

Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

Journal Article Expert Rev Anticancer Ther · August 2012 Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and bi ... Full text Link to item Cite

Bevacizumab for the treatment of high-grade glioma.

Journal Article Expert Opin Biol Ther · August 2012 INTRODUCTION: Gliomas are highly vascular and rich in vascular endothelial growth factor (VEGF) that promotes angiogenesis. Bevacizumab is a monoclonal antibody against VEGF inhibiting angiogenesis by preventing receptor activation. Phase II clinical trial ... Full text Link to item Cite

Epirubicin: is it like doxorubicin in breast cancer? A clinical review.

Journal Article Breast · April 2012 Anthracyclines are among the most effective chemotherapy treatments available for various types of cancer. The anthracyclines commonly used in treatment of breast cancer are either epirubicin or doxorubicin. Epirubicin is an epimer of doxorubicin with impo ... Full text Link to item Cite

Hormonal resistance in breast cancer: Evolving treatment strategies

Journal Article Current Breast Cancer Reports · March 1, 2012 About 70% of breast cancers are hormone receptor (HR) positive, meaning an estrogen receptor (ER) and/or a progesterone receptor (PgR) are present in the tumor. Compounds that modulate ER or PgR signaling, by either competing for estrogen binding to estrog ... Full text Cite

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.

Journal Article Ann Oncol · February 2012 BACKGROUND: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor approved for recurrent glioblastoma (GBM), metastatic breast, colorectal and non-small-cell lung cancers (NSCLC). There has been a potentially increased risk of i ... Full text Link to item Cite

Neurological complications of non-hodgkin lymphoma

Chapter · January 1, 2012 Non-Hodgkin lymphoma (NHL) can cause neurological symptoms and complications through direct involvement of the central or peripheral nervous system, in addition to paraneoplastic disorders. This chapter covers diagnosis and treatment of direct complication ... Full text Cite

A survey of suspected familial breast cancer in Iraqi Kurdish women.

Conference Journal of Clinical Oncology · May 20, 2011 Full text Cite

The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

Journal Article Curr Oncol Rep · February 2011 Knowledge of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) status is necessary for determining the optimal treatment of breast cancer patients. At the same time, the discordance between marker profi ... Full text Link to item Cite

Neurological complications of systemic cancer.

Journal Article Lancet Neurol · December 2010 Neurological complications of systemic cancer-those arising outside the nervous system-can be distressing, disabling, and sometimes fatal. Diagnosis is often difficult because different neurological disorders may present with similar signs and symptoms. Fu ... Full text Link to item Cite

Thrombocytopenia in solid tumors

Journal Article European journal of Clinical and Medical Oncology · September 9, 2010 Thrombocytopenia in patients with solid malignancy can be caused by bone marrow involvement or toxicity from anticancer therapy; however, it could rarely be the first presentation of a tumor such as breast cancer or lymphoma. Hematological paraneoplastic s ... Cite

Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.

Journal Article Ann Oncol · June 2010 BACKGROUND: Docetaxel (Taxotere) improve survival and prostate-specific antigen (PSA) response rates in patients with metastatic castrate-resistant prostate cancer (CRPC). We studied the combination of PI-88, an inhibitor of angiogenesis and heparanase act ... Full text Link to item Cite

Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.

Journal Article Intern Med J · June 2010 Conventional cytotoxic chemotherapy is not usually effective in neuroendocrine tumours (NET). Somatostatin analogues (SSA) such as octreotide (Sandostatin; octreotide LAR and lanreotide) are typically used to treat symptoms caused by NET, but not as the pr ... Full text Link to item Cite

Anti-angiogenic therapy for high grade glioma

Journal Article · February 17, 2010 Full text Cite

Advances in the treatment of malignant gliomas.

Journal Article Curr Oncol Rep · January 2010 Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizum ... Full text Link to item Cite

Cardiac toxicity from sunitinib: Do we need to be more vigilant?

Journal Article Asia-Pacific Journal of Clinical Oncology · December 15, 2009 Full text Cite

Anti-angiogenic therapy for lung cancer

Journal Article Cochrane Database of Systematic Reviews · October 7, 2009 Full text Cite

Management of advanced neuroendocrine tumors with hepatic metastasis.

Journal Article J Clin Gastroenterol · October 2009 Neuroendocrine tumors (NETs) in general and specifically these gastroenteropancreatic-neuroendocrine tumors often present a considerable diagnostic and therapeutic challenge, especially those that behave in an aggressive fashion. The majority of tumors are ... Full text Link to item Cite

Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?

Journal Article J Clin Neurosci · June 2009 Temozolomide (TMZ) is an alkylating agent used in the management of gliomas. Although TMZ is generally safe and acute toxicity is well documented, there are limited data on long-term toxicities. We present three patients with glioma; all patients started o ... Full text Link to item Cite

ABSENCE OF EVIDENCE IS NO EVIDENCE OF ABSENCE

Conference NEURO-ONCOLOGY · October 1, 2008 Link to item Cite

Chemotherapy in the elderly

Conference Cancer Forum · March 1, 2008 The number of elderly patients with malignancy is growing and is likely to have a major impact on resources, quality of care, health economics and treatment options. Decisions regarding treatment options with chemotherapy are limited by the scarcity of dat ... Cite

Chemotherapy in the elderly.

Journal Article N Engl J Med · February 21, 2002 Full text Link to item Cite